论文部分内容阅读
目的探析阿托品治疗儿童屈光不正的临床疗效及安全性,为临床用药提供参考。方法选取2013年12月至2014年5月入院治疗的屈光不正儿童患者80例。采取抽样法,以患者入院先后顺序将其随机分为对照组和观察组,每组40例。对照组患者给予常规治疗,观察组患者在对照组基础上实施阿托品疗法,治疗周期为6个月,收集患儿6个月内验光屈光度检查情况。结果对照组患者实施常规治疗屈光不正后,屈光度变化不显著,差异无统计学意义(P>0.05);观察组在给予阿托品治疗后,屈光度变化明显,差异有统计学意义(P<0.05)。结论阿托品疗法治疗儿童屈光不正,可有效改善患者屈光不正情况,缓解患者近视,且不良反应少,临床应用价值值得关注。
Objective To explore the clinical efficacy and safety of atropine in the treatment of refractive errors in children and provide reference for clinical medication. Methods Eighty patients with refractive errors admitted from December 2013 to May 2014 were selected. Sampling method was used to randomly divide the patients into control group and observation group with 40 cases in each group. The patients in the control group were given routine treatment. The patients in the observation group were treated with atropine on the basis of the control group. The treatment period was 6 months. The refraction examination within 6 months was collected. Results There was no significant difference in diopter (P> 0.05) between the control group and the control group after routine treatment of refractive errors, but the difference was statistically significant (P <0.05) . Conclusion Atropine treatment of children with refractive errors, can effectively improve the patient’s refractive errors, alleviate myopia, and fewer adverse reactions, the clinical application of the value of concern.